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Abstract
Background: International evidence-based guidelines recommend physical exercise to form part of standard care
for all cancer survivors. However, at present, the optimum exercise intensity is unclear. Therefore, we aimed to
evaluate the effectiveness of a high intensity (HI) and low-to-moderate intensity (LMI) resistance and endurance
exercise program compared with a wait list control (WLC) group on physical fitness and fatigue in a mixed group
of cancer survivors who completed primary cancer treatment, including chemotherapy.
Methods: Overall, 277 cancer survivors were randomized to 12 weeks of HI exercise (n = 91), LMI exercise (n = 95), or
WLC (n = 91). Both interventions were identical with respect to exercise type, duration and frequency, and only differed
in intensity. Measurements were performed at baseline (4–6 weeks after primary treatment) and post-intervention. The
primary outcomes were cardiorespiratory fitness (peakVO2), muscle strength (grip strength and 30-second chair-stand
test), and self-reported fatigue (Multidimensional Fatigue Inventory; MFI). Secondary outcomes included health-related
quality of life, physical activity, daily functioning, body composition, mood, and sleep disturbances. Multilevel
linear regression analyses were performed to estimate intervention effects using an intention-to-treat principle.
Results: In the HI and LMI groups, 74 % and 70 % of the participants attended more than 80 % of the prescribed
exercise sessions, respectively (P = 0.53). HI (β = 2.2; 95 % CI, 1.2–3.1) and LMI (β = 1.3; 95 % CI, 0.3–2.3) exercise showed
significantly larger improvements in peakVO2 compared to WLC. Improvements in peakVO2 were larger for HI than LMI
exercise (β = 0.9; 95 % CI, −0.1 to 1.9), but the difference was not statistically significant (P = 0.08). No intervention
effects were found for grip strength and the 30-second chair-stand test. HI and LMI exercise significantly
reduced general and physical fatigue and reduced activity (MFI subscales) compared to WLC, with no
significant differences between both interventions. Finally, compared to WLC, we found benefits in global
quality of life and anxiety after HI exercise, improved physical functioning after HI and LMI exercise, and less
problems at work after LMI exercise.
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Conclusions: Shortly after completion of cancer treatment, both HI and LMI exercise were safe and effective.
There may be a dose–response relationship between exercise intensity and peakVO2, favoring HI exercise. HI
and LMI exercise were equally effective in reducing general and physical fatigue.
Trial registration: This study was registered at the Netherlands Trial Register [NTR2153] on the 5th of January 2010.
Keywords: Exercise, Fatigue, Neoplasms, Physical fitness, Quality of life
Background
Exercise during and after cancer treatment is safe and
may increase physical fitness [1], reduce fatigue [2], and
enhance the health-related quality of life (HRQoL) [3].
International evidence-based guidelines have endorsed
these findings and recommend physical exercise to be
part of standard care for all cancer survivors [4].
However, current exercise recommendations remain
rather generic. Defining the optimal mode, frequency,
volume, and intensity of exercise in cancer survivors
may help to further improve the effectiveness of exer-
cise programs [5].
The effects of different exercise modes and volumes in
breast cancer survivors during chemotherapy have been
previously evaluated in large randomized controlled
trials (RCT) [6, 7]. Yet, only two [8, 9] relatively small
RCTs have studied the effects of different exercise inten-
sities in cancer survivors after completion of primary
cancer treatment. Burnham et al. [8] compared moder-
ate versus low intensity aerobic exercise in breast cancer
survivors (n = 18) and reported that both exercise pro-
grams improved cardiorespiratory fitness, compared to
usual care, with no differences in effects between the
interventions [8]. Gibbs et al. [9] reported larger im-
provements in cardiorespiratory fitness in breast cancer
survivors (n = 73) after high intensity (HI) resistance ex-
ercise compared to low intensity exercise and usual care.
Both high and low intensity exercise significantly im-
proved muscle strength and reduced general fatigue
compared to usual care, but no significant differences
between the interventions were found [9]. Due to the
scarcity of studies and small sample sizes, more insight
into the effects of different exercise intensities is war-
ranted to bridge this gap in existing knowledge.
Herein, we report results of the Resistance and
Endurance exercise After ChemoTherapy (REACT)
study [10]. This is the largest RCT to date that has exam-
ined the effectiveness of a HI and a low-to-moderate in-
tensity (LMI) resistance and endurance exercise program
compared with a wait list control (WLC) group in cancer
survivors who had completed primary cancer treatment
with cardiorespiratory fitness, muscle strength, and fatigue
as primary outcomes. We included HRQoL, physical ac-
tivity, daily functioning, body composition, mood, and
sleep disturbances as secondary outcomes.
Methods
Design
The REACT study was a RCT including three study
arms: HI exercise, LMI exercise, and a WLC group. The
study was approved by the Medical Ethics Committee of
the VU University Medical Center (Amsterdam) and the
local ethical boards of all participating hospitals, including
Máxima Medical Center (Eindhoven and Veldhoven),
Catharina Hospital (Eindhoven), Elkerliek Hospital (Hel-
mond), St. Anna Hospital (Geldrop), VieCuri Medical
Center (Venray and Venlo), Zuwe Hofpoort Hospital
(Woerden), St. Antonius Hospital (Utrecht and Nieuwe-
gein), Academic Medical Center (Amsterdam), and Eras-
mus MC University Medical Center (Rotterdam).
Participants
Between 2011 and 2013, patients were recruited from nine
Dutch hospitals. Patients aged ≥18 years with histologi-
cally confirmed breast, colon, ovarian, cervix or testis
cancer, or lymphomas with no indication of recurrent or
progressive disease, who had completed (adjuvant or neo-
adjuvant) chemotherapy were invited to participate.
Exclusion criteria were (1) not being able to perform basic
activities of daily living, (2) cognitive disorders or severe
emotional instability, (3) other serious diseases that might
hamper patients’ capacity of carrying out HI exercise
(e.g. severe heart failure), and (4) inability to understand the
Dutch language. Written informed consent was obtained
from all patients prior to participation.
Randomization and blinding
After baseline assessments, participants were stratified by
cancer type and hospital, and randomly assigned to one of
the three study arms. An independent research assistant
performed the randomization by using a table of random
numbers generated from statistical software. Allocation
sequence was concealed from the clinical and research
staff. Following randomization, both HI and LMI groups
commenced their 12-week exercise program. Participants
from the WLC group were similarly randomly allocated to
HI or LMI. However, they started exercising after the
post-test assessment. Study outcomes of objective phys-
ical assessments were assessed by trained and blinded
assessors and participants were instructed not to re-
veal their group allocation.
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Exercise interventions
Full details of the HI and LMI programs are described
elsewhere [10]. Both interventions were identical with
respect to exercise type, duration and frequency, and dif-
fered only in intensity (Table 1) [10]. After medical clear-
ance by a sports physician, exercise sessions were given
twice per week for 12 weeks under supervision of a
physiotherapist.
Both exercise programs included six resistance exer-
cises targeting large muscle groups with a frequency of
two sets of 10 repetitions. Workload per exercise was
defined by an indirect one-repetition maximum (1-RM)
measurement. HI resistance exercises started in the first
week at 70 % of 1-RM (Table 1) and gradually increased
to 85 % of 1-RM in week 12, whereas LMI resistance
exercises started at 40 % of 1-RM gradually increased to
55 % of 1-RM. Every 4 weeks (weeks 5 and 9) the
physiotherapist conducted the indirect 1-RM test and
adjusted the workload accordingly.
Furthermore, both programs included two types of
endurance interval exercises, aiming to maximize im-
provements in cardiorespiratory fitness. In the first
4 weeks, patients cycled 2 × 8 minutes with alternating
workloads. Workloads were defined by the maximum
short exercise capacity (MSEC) estimated by the steep
ramp test [11]. The HI group cycled 30 seconds at a
workload of 65 % of the MSEC and 60 seconds at 30 %,
and the LMI group cycled 30 seconds at a workload of
45 % of the MSEC and 60 seconds at 30 %. Once the
first 4 weeks were accomplished, the duration of the
latter block was reduced from 60 to 30 seconds in both
exercise programs. Every 4 weeks, the physiotherapist
evaluated training progress by means of the steep ramp
test, and the workload was adjusted accordingly.
From the fifth week onwards, one additional endur-
ance interval session was performed in exchange for one
block of 8 minutes cycling. This interval session con-
sisted of 3 × 5 minutes cycling at constant workload,
with 1 minute rest between each bout. Participants
trained on ergometers (e.g. cycle ergometer or tread-
mill). The workload was defined by the heart rate re-
serve (HRR) using the Karvonen formula [12]. The HI
group trained at ≥80 % of HRR and the LMI group at
40–50 % of HRR.
The physiotherapists closely monitored individual ses-
sion attendance. In addition, they applied behavioral mo-
tivation counseling techniques to overcome possible
exercise barriers and to encourage participants to start
or maintain a physically active lifestyle outside the exer-
cise program. Participants were stimulated to be physic-
ally active at moderate intensity for at least 30 minutes,
three times per week complementary to the supervised
exercise program and regardless of their group alloca-
tion. The combination of supervised exercise, twice a
week, and home-based exercises, three times a week,
meets the recommendations of the evidence-based phys-
ical activity guidelines for cancer survivors [4].
Measurements
All outcome measures were assessed at baseline (4–6
weeks after completion of primary cancer treatment)
and after 12 weeks. Details on the validity and reliability
of the different outcome measures have been described
previously [13].
Primary outcome measures
Cardiorespiratory fitness was measured during a max-
imal exercise test on an electronically braked cycle erg-
ometer according to a ramp protocol, aiming to achieve
peak oxygen uptake (peakVO2, in mL/kg/min) within 8–
12 minutes [14]. Expired gases were collected and ana-
lyzed breath by breath to determine peakVO2 [14].
PeakVO2 was defined as the highest values of oxygen
consumption averaged over a 15 seconds interval within
the last minute of exercise. After each test, peakVO2,
peak power output (in watt), and the ventilatory thresh-
old determined by the oxygen equivalent method were
recorded.
Upper body muscle strength was assessed using a
JAMAR hand grip dynamometer [15]. Participants were
instructed to complete three measurements for each
hand while alternating sides. The mean score of the
three attempts of a participants’ dominant hand was
used as indicator for upper body muscle strength. Lower
Table 1 Exercise intensities of the high intensity (HI) and low-to-moderate intensity (LMI) resistance and endurance exercise programs
Resistance exercises (1-RM) a Endurance interval exercises Endurance interval exercises Counseling
(six exercises targeting the
large muscle groups)
Part A (MSEC) a (8 min
alternating workload)
Part B (HRR) a (3 × 5 min
constant workload)
HI exercise b 70–85 % 30/65 % ≥80 % Participants were encouraged to start
or maintain a physically active lifestyle
in addition to the supervised exercise
sessions
LMI exercise b 40–55 % 30/45 % 40–50 %
1-RM, One-repetition maximum; MSEC, Maximum short exercise capacity; HRR, Heart rate reserve
a Every 4 weeks (weeks 1, 5, and 9), the physiotherapist evaluated training progress and adjusted the workload accordingly
b Exercises were accompanied with BORG scores and heart rate monitors to guide the physiotherapists. In cases where the training intensity seemed too high or
too low, the 1-RM, MSEC, or HRR were reassessed
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body function was assessed using the 30-second chair-
stand test [16]. Participants were instructed to rise to a
full stand and return to the original seated position as
quickly as possible. The total number of times that the
participant raised to a full stand in 30 seconds was re-
ported. Both the hand grip strength and 30-second
chair-stand tests are valid outcome measures and can be
used to characterize upper body strength and lower body
function [15, 17].
Fatigue was assessed using the Multidimensional
Fatigue Inventory (MFI) questionnaire [18]. The MFI
is a validated questionnaire and consists of 20 items
divided into five subscales: general fatigue, physical
fatigue, reduced physical activity, reduced motivation,
and mental fatigue. Participants were asked to indicate, on
a 1–5 scale, to what extent the particular item applied to
them, with a maximum sum score of 20 points per
subscale.
Secondary outcome measures
HRQoL was measured using the European Organisation
Research and Treatment of Cancer-Quality of Life
questionnaire-Core 30 [19], anxiety and depression by
the Hospital Anxiety and Depression Scale [20], sleep
disturbances with the Pittsburgh Sleep Quality Index
[21], participation in daily life using the Impact on
Participation and Autonomy (IPA) [22], and self-re-
ported physical activity (PA) using the Physical Activity
Scale for the Elderly questionnaire [23]. Objective
measurement of PA was assessed with an accelerom-
eter (Actitrainer, Actigraph, Fort Walton Beach, USA)
using vertical accelerations converted into PA counts
per minute. Participants were instructed to wear the
accelerometer around the hips for seven consecutive
days during all waking hours. Raw data was recorded
in epochs of 60 seconds. A valid day of wearing-time
was defined as 10 hours and non-wearing time was
defined as 90 minutes of consecutive zero counts.
Raw data were processed using ActiLife Software version
6.10.2 (ActiGraph, Pensacola, Florida, USA). Body weight
was measured to the nearest 0.1 kg on a digital scale with
light cloths on and no shoes. Body height was measured
to the nearest 0.1 centimeters without shoes. Body mass
index was calculated from the measured body weight and
height accordingly. Thickness of four skinfolds in millime-
ters (biceps, triceps, suprailiac, and subscapular) was mea-
sured using a Harpenden skinfold caliper. The mean of
two consecutive measurements was used for further
analyses.
Assessments of covariates, session attendance, adverse
events, and contamination
Sociodemographic data were collected by self-report.
Clinical information was obtained from medical records.
Physiotherapists monitored session attendance in the ex-
ercise logs, as well as possible adverse events during the
intervention period. In addition, adverse events were
documented from the medical records for the interven-
tion and WLC groups. Contamination was assessed by
asking participants from the WLC group at the post-test
assessment if they had attended supervised exercise out-
side the study [24].
Power calculations
Power calculations were based on a previous uncon-
trolled trial evaluating the effectiveness of a HI resist-
ance and endurance exercise program in 119 cancer
survivors after completion of chemotherapy [25]. To be
able to detect a difference in peakVO2 of 3 mL/min/kg
(SD = 5.8), with a power of 0.80 and two-sided alpha of
0.05, 60 participants per group were needed at post-test
assessment. To compensate for loss to follow-up (20–
40 %) and taking into account the multilevel design, a
sample size of 280 was required. Additional power calcu-
lations (a power of 0.80 and alpha of 0.05) for fatigue
(MFI) and hand grip strength demonstrated that this
sample size of 280 would also be sufficient to detect a
clinically relevant difference of two points [26] on the MFI
questionnaire and a difference of 3 kg (10 % difference) in
hand grip strength.
Statistical analyses
Differences in age, sex, and diagnosis between partici-
pants and non-participants were examined using multi-
variable logistic regression analyses.
For all outcome measures, we used multivariable
multilevel linear regression analyses to evaluate differ-
ences in effects between the HI, LMI, and WLC groups.
Possible clustering of data within hospitals was taken
into account using a two-level structure with hospital as
the first level and participants as the second. Both inter-
ventions were simultaneously regressed on the post-test
value of the outcome, adjusted for the baseline value,
with age and sex as covariates. All analyses were per-
formed according to an intention-to-treat principle. In
addition, exploratory analyses were conducted to check
for effect modification by age, sex, and diagnosis (breast
cancer vs. other). To determine whether missing data
were selective, univariable logistic regression analyses
were conducted to examine baseline differences in the
primary outcomes between participants who com-
pleted post-test assessments and those who did not
(dropouts). We found no significant differences be-
tween the groups, and consequently, we considered
missing values to be at random. Since also dropout
rate was 10 %, we did not use imputation strategies
[27]. We considered P <0.05 to be statistically signifi-
cant. The statistical analyses were performed using
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MLwiN (version 2.22) and Statistical Package of Social
Sciences (SPSS, version 20.0).
Results
Of the 757 patients who were eligible, 277 (37 %) partici-
pated (Fig. 1). No significant differences in age, sex, and
diagnosis were found between the participants and non-
participants (Table 2). Furthermore, sociodemographic
and clinical data of the participants in the intervention
and WLC groups were balanced at baseline (Table 2). In
the HI and LMI groups, 74 % and 70 % of the partici-
pants attended more than 80 % of the prescribed exer-
cise sessions, respectively (P = 0.53; Fig. 1).
Exercise effects on primary outcomes
HI (β = 2.2; 95 % CI, 1.2–3.1) and LMI (β = 1.3; 95 % CI,
0.3–2.3) showed significantly larger improvements in
peakVO2 compared to WLC (Table 3). Improvement
in peakVO2 was larger for HI than LMI (β = 0.9; 95 %
CI, −0.1 to 1.9), but the difference was not statistically
significant (P = 0.08). Relative improvements in peakVO2
were 20 % and 15 % for HI and LMI, respectively, which is
in line with the relative improvements in healthy adults
after a 12-week exercise program [28]. No significant
intervention effects were found for grip strength and 30-
second chair-stand tests. Compared to WLC, both HI and
LMI showed significant improvements in general fatigue
(HI: β = −1.3; 95 % CI, −2.2 to −0.4 and LMI: β = −1.1;
95 % CI, −2.0 to −0.2), physical fatigue (HI: β = −2.0;
95 % CI, −2.9 to −1.1 and LMI: β = −1.4; 95 % CI, −2.3
to −0.5), and reduced activity (HI: β = −1.1; 95 % CI, −1.9
to −0.2 and LMI: β = −1.2; 95 % CI, −2.1 to −0.3), with no
significant differences between both interventions. HI
showed a beneficial effect on motivation compared to
LMI (β = −0.8; 95 % CI, −1.5 to −0.03) and WLC (β = −1.2;
95 % CI, −1.9 to −0.4), with no significant differences
between LMI and WLC. Furthermore, HI showed a
significant reduction in mental fatigue compared to
WLC (β = −0.9; 95 % CI, −1.7 to −0.2). The effects on
peakVO2 were modified by age (HI: βinteraction = −0.2;
Fig. 1 Patients flowchart of the REACT study. HI, High intensity exercise; LMI, Low-to-moderate intensity exercise; WLC, Wait list control group;
PRO, Patient reported outcomes
Kampshoff et al. BMC Medicine  (2015) 13:275 Page 5 of 12
Table 2 Baseline characteristics of participants and non-participants
Characteristics HI LMI WLC Non-participants
n = 91 n = 95 n = 91 n = 479
Sociodemographic
Age, mean (SD) years 54 (11.0) 53 (11.3) 54 (10.9) 55 (11.6)
Sex, n (%) male a 18 (20) 17 (18) 20 (22) 77 (16)
Married/living together, n (%) yes 73 (80) f 87 (92) f 72 (79) f
Education, n (%) b
Low 19 (21) 12 (13) 16 (18)
Intermediate 37 (41) 43 (46) 42 (46)
High 34 (38) 38 (40) 33 (36)
Being employed, n (%)
Employed 54 (59) 56 (58) 57 (63)
Not employed 25 (28) 22 (23) 19 (21)
Retirement 12 (13) 17 (18) 15 (17)
Smoking, n (%) yes c 7 (8) 5 (5) 5 (6)
Comorbidity, n (%) yes 12 (13) 8 (8) 10 (11)
Sport history, n (%) yes d 45 (50) 61 (65) 49 (54)
Exercise during chemotherapy, n (%) yes b 21 (23) 21 (22) 10 (11)
Clinical
Diagnosis, n (%) e
Breast 62 (68) 62 (65) 57 (63) 309 (65)
Colon 15 (17) 19 (20) 15 (17) 85 (18)
Ovarian 4 (4) 3 (3) 5 (6) 23 (5)
Lymphoma 9 (10) 9 (9) 8 (9) 47 (10)
Cervix 0 (0) 2 (2) 2 (2) 12 (3)
Testis 1 (1) 0 (0) 4 (4) 4 (1)
Stage of disease, n (%)
Stage I–II 68 (75) 57 (60) 62 (68)
Stage II–IV 23 (25) 38 (40) 29 (32)
Type of treatment, n (%) yes
Surgery 83 (91) 87 (92) 80 (88)
Radiation therapy 46 (51) 41 (43) 48 (53)
Surgery + radiation therapy 41 (45) 39 (41) 46 (51)
Immunotherapy 16 (18) 25 (26) 18 (20)
Hormonal therapy 45 (50) 40 (42) 43 (47)
Type of chemotherapy, n (%)
TAC 39 (43) 33 (34) 31 (34)
FEC 7 (8) 7 (7) 5 (6)
TAC/FEC combinations 15 (17) 21 (22) 17 (19)
Capecitabine and oxaliplatin 8 (9) 11 (12) 7 (8)
Oxaliplatin combinations 7 (8) 8 (8) 7 (8)
Carboplatin and paclitaxel 4 (4) 4 (4) 10 (11)
CHOP 5 (6) 6 (6) 7 (8)
ABVD 4 (4) 2 (2) 2 (2)
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95 % CI, −0.3 to −0.1; P = 0.000 and LMI: βinteraction = −0.1;
95 % CI, −0.2 to −0.01; P = 0.03), indicating larger effects
for younger participants. No significant interaction effects
for gender or diagnosis were found for physical fitness or
fatigue.
Exercise effects on secondary outcomes
HI showed significantly larger improvements in global
quality of life (QoL) (β = 5.9; 95 % CI, 2.0–9.8) and re-
duced anxiety (β = −1.0; 95 % CI, −1.7 to −0.3) compared
to WLC (Table 4). Significantly larger improvements in
physical functioning were found for both exercise pro-
grams compared to WLC (HI: β = 3.1; 95 % CI, 0.7–5.5
and LMI: β = 4.1; 95 % CI, 1.6–6.6), with no significant
differences between the exercise programs. The effects
of HI on global QoL were larger for younger participants
(βinteraction = −0.4; 95 % CI, −0.8 to −0.04; P = 0.03) and
for participants with breast cancer (βinteraction = 9.5;
95 % CI, 1.4–17.8; P = 0.02). Women showed larger
improvements after HI in global QoL (βinteraction = 11.1;
95 % CI, 1.8–20.4; P = 0.02) and physical functioning
(βinteraction = 7.1; 95 % CI, 1.2–13.0; P = 0.02) than
men. No significant between-group differences were
found for role, emotional, cognitive, and social func-
tioning, body composition, sleep disturbances, phys-
ical activity levels, and depression, nor for the IPA
questionnaire, except for significantly lower scores on
the ‘problems at work’ subscale after LMI (β = −0.3;
95 % CI, −0.6 to −0.02) compared to WLC (Table 4,
14 subscales of IPA are not presented).
Adverse events
No adverse events directly related to the exercise pro-
grams were reported. Nevertheless, five participants re-
ported disease recurrence and withdrew from the study,
four participants withdrew from the study because of co-
morbidities not related to the interventions (i.e. heart
failure, hernia nuclei pulposi, ankle fracture, and abdom-
inal adhesions), six participants withdrew from the study
because two exercise sessions per week was too much,
and 11 participants reported musculoskeletal problems
at the start of the exercise program and they continued
with a modified program (despite program modifica-
tions, four of these participants withdrew).
Discussion
We performed a head-to-head comparison of a 12-week
HI and LMI exercise program compared to WLC shortly
after completion of primary cancer treatment in a large
group of cancer survivors with mixed diagnoses. This
allowed us to determine differences in effects of exercise
intensity on physical fitness, fatigue, and HRQoL.
Both HI and LMI significantly improved peakVO2
compared to WLC. We found mean peakVO2 improve-
ments of 4.4 mL/kg/min after HI and 3.3 mL/kg/min
after LMI, which is in line with the 3.3 mL/kg/min in-
crease reported in a meta-analysis of three RCTs among
patients who completed cancer treatment [1]. Improve-
ments in peakVO2 tended to be larger after HI than
LMI, suggesting a dose–response relationship for exer-
cise intensity. However, this should be confirmed in fu-
ture studies. Improving peakVO2 of cancer survivors is
particularly important because, compared to healthy
adults, their peakVO2 levels are very poor [29]. Higher
peakVO2 levels in cancer survivors have been associated
with lower fatigue and higher HRQoL [25, 30]. In
addition, results from observational studies showed a
positive association between peakVO2 and survival [31],
but causality needs to be established.
In contrast to a meta-analysis examining effects of re-
sistance exercises on muscle strength [32], we found no
significant intervention effects on the grip strength and
30-second chair-stand tests. However, the indirect 1-RM
tests that were conducted every 4 weeks as part of the
exercise programs indicated an improvement of 37 % on
the leg press and 34 % on the vertical row. Therefore,
the current lack of intervention effects may be related to
our choice of outcome measures. Although grip strength
is a reliable and valid measure of general upper body
muscle strength [15], it may not be sensitive enough to
detect improvements in muscle strength of the upper
arm and shoulder [33]. Comparably, the 30-second
Table 2 Baseline characteristics of participants and non-participants (Continued)
Cisplatin 0 2 (2) 1 (1)
BEP 1 (1) 0 3 (3)
Other 1 (1) 1 (1) 1 (1)
HI, High intensity; LMI, Low-to-moderate intensity; WLC, Wait list control; FEC, Fluorouracil, epirubicin, cyclophosphamide; TAC, Taxotere, adriamycin, cyclophosphamide;
CHOP, Cyclophosphamide, doxorubicin, vincristine, prednisone; ABVD, Doxorubicin, bleomycin, vinblastine, dacarbazine; BEP, Bleomycin, etoposide, cisplatin
a n-4 (non-participants)
b n-3
c n-4
d n-1
e n-1 (non-participants)
f P <0.05
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Table 3 Mean (SD) values of baseline and post-test measurement differences in effects on primary outcomes physical fitness and fatigue between groups a
High intensity (HI) Low-to-moderate intensity (LMI) Wait list control (WLC) HI vs. WLC LMI vs. WLC HI vs. LMI
Baseline
mean (SD)
Post-test
mean (SD)
Baseline
mean (SD)
Post-test
mean (SD)
Baseline
mean (SD)
Post-test
mean (SD)
β (95 % CI) β (95 % CI) β (95 % CI)
Primary outcomes
Cardiorespiratory fitness b
PeakVO2 (mL/kg/min) 21.9 (6.5) 26.3 (7.6) 22.3 (5.9) 25.6 (6.5) 21.5 (5.5) 23.8 (5.9) 2.2 (1.2 to 3.1)
h 1.3 (0.3 to 2.3) h 0.9 (−0.1 to 1.9) i
Peak power output (W) 136 (46) 163 (53) 134 (43) 154 (45) 135 (42) 150 (43) 12.6 (7.7 to 17.5) h 5.0 (0.01 to 9.9) h 7.6 (2.5 to 12.7) h
Ventilatory threshold (mL/kg/min) 15.6 (4.1) 18.8 (4.7) 16.2 (4.8) 18.8 (5.2) 15.5 (4.8) 17.3 (5.6) 1.5 (0.4 to 2.5) h 1.1 (0.1 to 2.2) h 0.4 (−0.7 to 1.4)
Muscle strength
Sit to stand (stands) c 17 (4.4) 19 (4.9) 16 (3.6) 19 (4.8) 16 (3.6) 18 (3.9) 0.2 (−0.8 to 1.1) 0.6 (−0.3 to 1.5) −0.5 (−1.4 to 0.4)
Grip strength (kg) d 32.5 (9.7) 34.4 (10.5) 32.9 (9.8) 34.9 (9.8) 33.5 (9.5) 35.5 (10.6) −0.3 (−1.3 to 0.7) 0.3 (−0.7 to 1.3) −0.6 (−1.6 to 0.5)
Fatigue (Range 4–20) e
General fatigue f 12.8 (3.8) 10.0 (3.3) 12.6 (4.1) 10.1 (3.4) 12.7 (4.2) 11.3 (4.1) −1.3 (−2.2 to −0.4) h −1.1 (−2.0 to −0.2) h −0.2 (−1.1 to 0.7)
Physical fatigue f 12.8 (3.9) 9,0 (3.2) 12.3 (3.9) 9.4 (3.6) 13.2 (4.0) 11.2 (3.9) −2.0 (−2.9 to −1.1) h −1.4 (−2.3 to −0.5) h −0.6 (−1.6 to 0.3)
Reduced activity g 12.2 (3.8) 9.6 (3.2) 11.5 (3.6) 9.1 (3.5) 11.8 (3.6) 10.5 (3.6) −1.1 (−1.9 to −0.2) h −1.2 (−2.1 to −0.3) h 0.1 (−0.8 to 1.0)
Reduced motivation g 9.4 (3.2) 7.9 (2.6) 9.0 (3.0) 8.5 (3.1) 8.6 (3.1) 8.7 (3.2) −1.2 (−1.9 to −0.4) h −0.4 (−1.1 to 0.4) −0.8 (−1.5 to −0.03) h
Mental fatigue f 11.1 (4.2) 9.8 (3.7) 10.9 (4.0) 9.9 (3.6) 10.7 (4.1) 10.5 (4.1) −0.9 (−1.7 to −0.2) h −0.7 (−1.5 to 0.1) i −0.2 (−1.1 to 0.6)
a Adjusted model, corrected for age and sex
b Missing due to technical problems (n = 5), musculoskeletal problems (n = 1), or discomfort (n = 6)
c Missing due to musculoskeletal problems (n = 2)
d Missing due to technical problems (n = 3) or musculoskeletal problems (n = 2)
e Higher score means a higher level of self-reported fatigue in all subscales
f Missing due to incomplete questionnaire (n = 1)
g Missing due to incomplete questionnaire (n = 2)
h P <0.05)
i 0.05 ≤ P <0.10
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Table 4 Baseline and post-test measurements and adjusted between group differences on secondary outcomes of health-related quality of life, body composition, sleep disturbances,
physical activity, and distress a
High intensity (HI) Low-to-moderate intensity (LMI) Wait list control (WLC) HI vs. WLC LMI vs. WLC HI vs. LMI
Baseline
mean (SD)
Post-test
mean (SD)
Baseline
mean (SD)
Post-test
mean (SD)
Baseline
mean (SD)
Post-test
mean (SD)
β (95 % CI) β (95 % CI) β (95 % CI)
Health-related quality of life (Range 0–100) b
Global quality of life c 72.8 (15.3) 82.0 (13.6) 73.6 (17.2) 79.7 (16.1) 71.0 (16.5) 75.3 (15.4) 5.9 (2.0 to 9.8) m 3.3 (−0.6 to 7.2) 2.6 (−1.4 to 6.6)
Physical functioning 82.0 (13.8) 88.1 (9.5) 83.0 (12.2) 89.6 (10.2) 80.2 (15.4) 84.1 (13.1) 3.1 (0.7 to 5.5) m 4.1 (1.6 to 6.6) m −1.0 (−3.5 to 1.5)
Role functioning c 73.7 (25.1) 82.5 (21.4) 69.2 (25.8) 83.5 (21.1) 67.4 (25.6) 82.0 (21.4) −2.1 (−7.6 to 3.3) 0.8 (−4.7 to 6.3) −3.0 (−8.6 to 2.7)
Emotional functioning c 86.0 (15.9) 88.3 (15.3) 82.9 (16.3) 84.0 (17.3) 83.5 (17.0) 83.3 (17.5) 3.3 (−0.4 to 7.1) 1.1 (−2.7 to 4.9) 2.2 (−1.7 to 6.1)
Cognitive functioning c 79.9 (22.5) 84.3 (17.5) 78.0 (21.4) 80.3 (19.5) 76.7 (22.7) 80.6 (21.1) 2.0 (−2.4 to 6.3) −0.9 (−5.3 to 3.6) 2.8 (−1.7 to 7.3)
Social functioning c 78.3 (22.0) 89,6 (15.1) 78.2 (20.0) 86.1 (20.0) 75.6 (24.6) 85.2 (21.7) 3.1 (−1.7 to 7.9) −0.2 (−5.1 to 4.7) 3.3 (−1.7 to 8.3)
Body composition
Body mass index, kg/m2 26.8 (4.0) 26.8 (4.0) 26.3 (4.3) 26.5 (4.4) 27.7 (4.8) 27.7 (4.8) −0.001 (−0.3 to 0.3) 0.2 (−0.1 to 0.4) −0.2 (−0.4 to 0.1)
Sum of skinfolds, mm d 73.0 (20.7) 72.2 (22.7) 72.2 (30.1) 73.1 (29.6) 77.7 (32.0) 78.2 (31.6) −1.7 (−5.3 to 1.8) −0.3 (−3.9 to 3.4) −1.5 (−5.2 to 2.2)
Sleep disturbances (Range 0–21) e,f
10.3 (3.3) 9.9 (3.3) 10.9 (3.1) 10.7 (3.7) 10.1 (3.2) 9.9 (3.6) −0.2 (−1.0 to 0.6) 0.1 (−0.8 to 0.9) −0.2 (−1.1 to 0.6)
Physical activity
Self-reported PA g 93.0 (71.5) 117.6 (87.7) 106.1 (80.9) 129.0 (68.5) 96.2 (66.2) 121.2 (72.9) −2.0 (−20.7 to 16.7) 1.4 (−17.7 to 20.4) −3.4 (−22.8 to 16.0)
Accelerometer, counts per minute h,i 246 (95.8) 248 (106.3) 229 (91.0) 247 (76.6) 239 (89.5) 258 (87.0) −12.9 (40.3 to 14.5) −5.7 (−33.0 to 21.5) −7.2 (−35.4 to 21.0)
Distress (Range 0–21) j
Anxiety k 4.0 (3.0) 3.2 (2.9) 4.0 (3.0) 3.9 (3.3) 3.8 (2.8) 4.1 (3.0) −1.0 (−1.7 to −0.3) m −0.4 (−1.0 to 0.3) −0.6 (−1.3 to 0.1) n
Depression l 3.1 (2.7) 2.5 (2.6) 3.5 (3.2) 2.7 (2.8) 3.3 (2.8) 3.0 (3.2) −0.4 (−1.1 to 0.2) −0.4 (−1.1 to 0.2) −0.02 (−0.7 to 0.6)
a Adjusted model, corrected for age and sex
b Higher score means a higher level of self-reported HRQoL in all subscales
c Missing due to incomplete questionnaire (n = 1)
d Missing due to skin problems (n = 3)
e Higher score means poorer self-reported sleep quality
f Missing due to incomplete questionnaire (n = 58)
g Missing due to incomplete questionnaire (n = 1)
h Average counts for Y-axis
I Missing due to technical problems/insufficient wearing-time (n = 85)
j Higher score means a higher level of anxiety and depression in both subscales
k Missing due to incomplete questionnaire (n = 2)
l Missing due to incomplete questionnaire (n = 3)
m P <0.05
n 0.05 ≤ P <0.10
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chair-stand test is a reliable and valid functional test
[16], but may be prone to ceiling effects [34]. More
direct measures of muscle strength, such as isokinetic
dynamometers, may be more sensitive to detect changes
over time [35].
Compared to WLC, both HI and LMI resulted in sig-
nificant and clinically meaningful reductions in general
fatigue, physical fatigue, and reduced activity. These re-
sults support previous results of a meta-analysis [2],
showing that exercise significantly reduced cancer-
related fatigue compared to non-exercise control groups.
Interestingly, our results showed that exercise is benefi-
cial in reducing both general and physical components
of fatigue, regardless of the training intensity. From a
physiological point of view, it is most likely that exercise
counteracts physical fatigue [36]. Yet, HI also signifi-
cantly reduced mental components of fatigue, com-
pared to WLC. However, the intervention effects on
reduced motivation and mental fatigue were small
and may not be clinically relevant. Further research is
needed to investigate whether combinations of exer-
cise with cognitive behavioral therapy, stress manage-
ment, or sleep therapy may have larger benefits on
mental fatigue [37].
HI showed a significant and clinically meaningful
(>10 points) increase on global QoL compared to
WLC. Furthermore, HI and LMI significantly im-
proved self-reported physical functioning. However,
the improvements (6 points) may have small clinical
meaning [38]. Both findings support the positive effect on
global QoL and inconsistent findings on physical func-
tioning reported in a previous meta-analysis [3]. A better
understanding of the mechanisms underlying the ex-
ercise effects on HRQoL in cancer survivors may help
to further target exercise interventions to specific
HRQoL outcomes [39].
Previous meta-analyses reported small significant re-
ductions in depression [40] and anxiety [3] after exer-
cise. Our study supports these findings for anxiety, but
not for depression. It has been suggested that larger ef-
fects on depression may only be expected in cancer sur-
vivors with higher levels of depression [40]. Our baseline
data showed low mean values on the Hospital Anxiety
and Depression Scale for depression and anxiety, leaving
little room for improvement. Likewise, not many of our
participants reported sleep disturbances or problems in
daily functioning at baseline. Furthermore, we found no
increase in PA levels in both exercise groups. However,
our interventions included only a small component of
behavioral motivation counseling and accomplishing be-
havior change may require more specific PA promotion
strategies [41]. Finally, the lack of significant reductions
in body fat was consistent with previous research [42] and
not unanticipated, because both interventions focused on
physical exercise only and did not aim at losing body
weight by including a dietary component.
Strengths of this study include the direct comparison
between HI and LMI, a well-designed (e.g. blinded
outcome assessment, concealed allocation) multicenter
RCT including a large sample size, the use of valid and
reliable outcome measures, and intention-to-treat ana-
lyses. However, some limitations should be noted. First,
compared to WLC, the reported effect sizes could be
interpreted as modest. Nevertheless, the results from the
current study highlight that twice-a-week, supervised ex-
ercise for 12 weeks is superior to natural recovery. Since
adherence rates might have played a role in the magni-
tude of the effect sizes, a full report on adherence and
compliance rates is needed to provide further insight on
whether and how exercise components were delivered.
Furthermore, participants of WLC were asked to main-
tain their habitual daily PA pattern; however, 8 % of the
WLC participants engaged in weekly supervised exercise
sessions and this may have reduced the intervention ef-
fects as well. Secondly, although we recruited 277 pa-
tients, 65 % of the participants were diagnosed with
breast cancer and only small groups of other diagnosis
were included. Therefore, potential differences in effects
across different cancer types could not be established.
Yet, except for global QoL, we found no differences in
intervention effects between survivors of breast cancer
or other types of cancer. Finally, slightly higher dropout
rates were observed in LMI compared to the other
groups. This can be partly explained by higher recur-
rence of disease rates in LMI, which was most likely
coincidental.
Conclusion
In conclusion, the current study demonstrates that
supervised HI can be safely recommended to cancer
survivors shortly after completion of cancer treatment.
Because we found some indication for a dose–response
relationship for peakVO2, HI may be preferred to LMI
when aiming to improve peakVO2 levels in cancer survi-
vors. Yet , HI and LMI were equally beneficial in coun-
teracting general and physical fatigue. Additional
research should further disentangle the effects of differ-
ent exercise modes, frequencies, volumes, and intensities
among different subgroups of patients to optimize
evidence-based exercise recommendations for cancer
survivors.
Abbreviations
1-RM: One-repetition maximum; HI: High intensity; HRQoL: Health-related
quality of life; HRR: Heart rate reserve; IPA: Impact on Participation and
Autonomy; LMI: Low-to-moderate intensity; MFI: Multidimensional Fatigue
Inventory; MSEC: Maximum short exercise capacity; PA: Physical activity;
peakVO2: Peak oxygen uptake; QoL: Quality of life; RCT: Randomized
controlled trial; WLC: Wait list control.
Kampshoff et al. BMC Medicine  (2015) 13:275 Page 10 of 12
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
CK, LB, WM, JB, MC, and GS designed the study. GS and MN supported
patient recruitment and CK, LB, MC and GS provided study materials. CK,
LB, and JT performed statistical analysis. CK and LB drafted the manuscript.
WM, JB, MC, JT, MN, and GS critically revised the manuscript for important
intellectual content. LB, WM, and MC gave administrative, technical, and
material support. All authors read and approved the final manuscript and
take responsibility for the integrity of the data.
Acknowledgements
This study is part of the A-CaRe Program, http://www.a-care.org/home/. The
authors acknowledge the A-CaRe Clinical Research Group and thank all pa-
tients who participated in the trial. In addition, we thank the oncologists,
nurses, sports physicians and their laboratory staff, rehabilitation specialists,
and physical therapists for their support in conducting the trial. Furthermore,
the authors would like to acknowledge Astrid Broersen, Eric Buytels, and
Lars van Knippenberg for their contribution to the development of the
exercise programs. We wish to thank Karen van der Weiden, Charlotte de Kruif,
Joep van Kesteren, Michiel Greidanus, and Julie Heeren for their support in
patient recruitment and collection as well as assembly of data.
Funding
This work was supported by the Alpe d’HuZes/KWF Fund. The research grant
is provided by the Dutch Cancer Society [Grant number ALPE 2009–4619].
Both funders had no role in study design, data collection, analyses, and
interpretation presented in this manuscript nor in the decision of submission
for publication.
Author details
1VU University Medical Center, Department of Public & Occupational Health,
and the EMGO Institute for Health and Care Research, Amsterdam, The
Netherlands. 2VU University Medical Center, Department of Epidemiology
and Biostatistics and the EMGO Institute for Health and Care Research, De
Boelelaan 1089a, 1081 HV Amsterdam, The Netherlands. 3Máxima Medical
Center, Department of Sports Medicine, Veldhoven, The Netherlands.
4Máxima Oncology Center, Eindhoven and Veldhoven, The Netherlands.
Received: 2 June 2015 Accepted: 12 October 2015
References
1. Jones LW, Liang Y, Pituskin EN, Battaglini CL, Scott JM, Hornsby WE, et al.
Effect of exercise training on peak oxygen consumption in patients with
cancer: a meta-analysis. Oncologist. 2011;16:112–20.
2. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related
fatigue in adults. Cochrane Database Syst Rev. 2012;11:CD006145.
3. Mishra SI, Schrerer RW, Geigle PM, Berlanstein DR, Topaloglu O, Gotay CC, et
al. Exercise interventions on health-related quality of life for cancer
survivors. Cochrane Database Syst Rev. 2012;8:CD007566.
4. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA,
Pinto BM, et al. American College of Sports Medicine roundtable on
exercise guidelines for cancer survivors. Med Sci Sports Exerc.
2010;42:1409–26.
5. Buffart LM, Galvao DA, Brug J, Chinapaw MJ, Newton RU. Evidence-based
physical activity guidelines for cancer survivors: current guidelines,
knowledge gaps and future research directions. Cancer Treat Rev.
2014;40(2):327–40.
6. Courneya KS, McKenzie DC, Mackey JR, Gelmon K, Friedenreich CM, Yasui Y,
et al. Effects of exercise dose and type during breast cancer chemotherapy:
multicenter randomized trial. J Natl Cancer Inst. 2013;105:1821–32.
7. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, et
al. Effects of aerobic and resistance exercise in breast cancer patients
receiving adjuvant chemotherapy: a multicenter randomized controlled trial.
J Clin Oncol. 2007;25:4396–404.
8. Burnham TR, Wilcox A. Effects of exercise on physiological and
psychological variables in cancer survivors. Med Sci Sports Exerc.
2002;34:1863–7.
9. Gibbs Z. Exercise for breast cancer patients with lymphedema. Australian
New Zealand Clinical Trials Registry. 2012. ACTRN12612000256875.
www.anzctr.org.au. Accessed 27 August 2015.
10. Kampshoff CS, Buffart LM, Schep G, van Mechelen W, Brug J, Chinapaw MJ.
Design of the Resistance and Endurance exercise After ChemoTherapy
(REACT) study: a randomized controlled trial to evaluate the effectiveness
and cost-effectiveness of exercise interventions after chemotherapy on
physical fitness and fatigue. BMC Cancer. 2010;10:658.
11. De Backer I, Schep G, Hoogeveen A, Vreugdenhil G, Kester AD,
van Breda E. Exercise testing and training in a cancer rehabilitation
program: the advantage of the steep ramp test. Arch Phys Med
Rehabil. 2007;88:610–6.
12. Karvonen J, Vuorimaa T. Heart rate and exercise intensity during sports
activities. Practical application. Sports Med. 1988;5:303–11.
13. Chinapaw MJ, Buffart LM, van Mechelen W, Schep G, Aaronson NK,
van Harten WH, et al. Alpe d’HuZes Cancer Rehabilitation (A-CaRe) Research:
four randomized controlled exercise trials and economic evaluations in cancer
patients and survivors. Int J Behav Med. 2012;19:143–56.
14. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, et al. Clinician’s
guide to cardiopulmonary exercise testing in adults: a scientific statement
from the American Heart Association. Circulation. 2010;122:191–225.
15. Bohannon RW. Hand-grip dynamometry provides a valid indication of
upper extremity strength impairment in home care patients. J Hand Ther.
1998;11:258–60.
16. Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower
body strength in community-residing older adults. Res Q Exerc Sport.
1999;70:113–9.
17. Rikli RE, Jones CJ. Development and validation of a functional fitness test for
community-residing older adults. J Aging Phys Activity. 1999;7:129–61.
18. Smets EM, Garssen B, Bonke B, de Haes JC. The Multidimensional Fatigue
Inventory (MFI) psychometric qualities of an instrument to assess
fatigue. J Psychosom Res. 1995;39:315–25.
19. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al.
The European Organization for Research and Treatment of Cancer QLQ-C30:
a quality-of-life instrument for use in international clinical trials in oncology.
J Natl Cancer Inst. 1993;85:365–76.
20. Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, van Hemert AM.
A validation study of the Hospital Anxiety and Depression Scale (HADS) in
different groups of Dutch subjects. Psychol Med. 1997;27:363–70.
21. Buysse DJ, Reynolds III CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh
Sleep Quality Index: a new instrument for psychiatric practice and research.
Psychiatry Res. 1989;28:193–213.
22. Cardol M, Beelen A, van den Bos GA, De Jong BA, de Groot IJ, de Haan RJ.
Responsiveness of the impact on participation and autonomy questionnaire.
Arch Phys Med Rehabil. 2002;83:1524–9.
23. Washburn RA, Ficker JL. Physical Activity Scale for the Elderly (PASE): the
relationship with activity measured by a portable accelerometer. J Sports
Med Phys Fitness. 1999;39:336–40.
24. Courneya KS, Friedenreich CM, Sela RA, Quinney HA, Rhodes RE. Correlates
of adherence and contamination in a randomized controlled trial of
exercise in cancer survivors: an application of the theory of planned
behavior and the five factor model of personality. Ann Behav Med.
2002;24:257–68.
25. Buffart LM, De Backer IC, Schep G, Vreugdenhil A, Brug J, Chinapaw MJ.
Fatigue mediates the relationship between physical fitness and quality of
life in cancer survivors. J Sci Med Sport. 2013;16:99–104.
26. Purcell A, Fleming J, Bennett S, Burmeister B, Haines T. Determining the
minimal clinically important difference criteria for the Multidimensional
Fatigue Inventory in a radiotherapy population. Support Care Cancer.
2010;18:307–15.
27. Eekhout I, de Vet HC, Twisk JW, Brand JP, de Boer MR, Heymans MW.
Missing data in a multi-item instrument were best handled by multiple
imputation at the item score level. J Clin Epidemiol. 2014;67:335–42.
28. Pollock ML. The quantification of endurance training programs. Exerc Sport
Sci Rev. 1973;1:155–88.
29. Schneider CM, Repka CP, Brown JM, Lalonde TL, Dallow KT, Barlow CE, et al.
Demonstration of the need for cardiovascular and pulmonary normative
data for cancer survivors. Int J Sports Med. 2014;35:1134–7.
30. Herrero F, Balmer J, San Juan AF, Foster C, Fleck SJ, Perez M, et al. Is
cardiorespiratory fitness related to quality of life in survivors of breast
cancer? J Strength Cond Res. 2006;20:535–40.
Kampshoff et al. BMC Medicine  (2015) 13:275 Page 11 of 12
31. Schmid D, Leitzmann MF. Cardiorespiratory fitness as predictor of cancer
mortality: a systematic review and meta-analysis. Ann Oncol. 2015;26(2):272–8.
32. Strasser B, Steindorf K, Wiskemann J, Ulrich CM. Impact of resistance training in
cancer survivors: a meta-analysis. Med Sci Sports Exerc. 2013;45(11):2080–90.
33. Lamers I, Kelchtermans S, Baert I, Feys P. Upper limb assessment in multiple
sclerosis: a systematic review of outcome measures and their psychometric
properties. Arch Phys Med Rehabil. 2014;95:1184–200.
34. Baruth M, Wilcox S, Wegley S, Buchner DM, Ory MG, Phillips A, et al.
Changes in physical functioning in the active living every day program of
the active for life initiative(R). Int J Behav Med. 2011;18:199–208.
35. de Araujo Ribeiro Alvares JB, Rodrigues R, de Azevedo FR, da Silva BG,
Pinto RS, Vaz MA, et al. Inter-machine reliability of the Biodex and
Cybex isokinetic dynamometers for knee flexor/extensor isometric,
concentric and eccentric tests. Phys Ther Sport. 2015;16:59–65.
36. Dimeo F. Radiotherapy-related fatigue and exercise for cancer patients: a
review of the literature and suggestions for future research. Front Radiat
Ther Oncol. 2002;37:49–56.
37. Goedendorp MM, Gielissen MF, Verhagen CA, Bleijenberg G. Psychosocial
interventions for reducing fatigue during cancer treatment in adults.
Cochrane Database Syst Rev. 2009;1:CD006953.
38. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance
of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–44.
39. Buffart LM, Kalter J, Chinapaw MJ, Heymans MW, Aaronson NK, Courneya KS, et
al. Predicting OptimaL cAncer RehabIlitation and Supportive care (POLARIS):
rationale and design for meta-analyses of individual patient data of
randomized controlled trials that evaluate the effect of physical activity
and psychosocial interventions on health-related quality of life in
cancer survivors. Syst Rev. 2013;2:75.
40. Craft LL, Vaniterson EH, Helenowski IB, Rademaker AW, Courneya KS.
Exercise effects on depressive symptoms in cancer survivors: a systematic
review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012;21:3–19.
41. Short CE, James EL, Stacey F, Plotnikoff RC. A qualitative synthesis of trials
promoting physical activity behaviour change among post-treatment breast
cancer survivors. J Cancer Surviv. 2013;7:570–81.
42. Irwin ML, varez-Reeves M, Cadmus L, Mierzejewski E, Mayne ST, Yu H, et al.
Exercise improves body fat, lean mass, and bone mass in breast cancer
survivors. Obesity (Silver Spring). 2009;17:1534–41.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kampshoff et al. BMC Medicine  (2015) 13:275 Page 12 of 12
